A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer Metastatic
Interventions: DRUG: PF-03084014|DRUG: PF-03084014|DRUG: PF-03084014|DRUG: Docetaxel|DRUG: Docetaxel
Sponsor: Pfizer